DYRK1A inhibition as a novel treatment approach for Alzheimer's disease - Resubmission

Project: Research project

Project Details


Dr. Dunckley and his team will perform characterization of DYR compounds using in vitro and cell-based assays. He will also perform in vivo testing of select, optimized compounds in the 3XTg-AD mouse model and conduct behavioral and neuropathological experiments on treated and untreated cohorts.

Effective start/end date4/1/202/28/21


  • HHS: National Institutes of Health (NIH): $1,075,080.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.